Innovative Therapy for Neovascular Age-Related Macular Degeneration

About Us

Orsight Pharma is at the forefront of developing an innovative drug for Neovascular Age-Related Macular Degeneration (nAMD or wet AMD), an advanced form of eye disease that is the leading cause of severe vision loss and blindness in developed countries. At Orsight Pharma, we are dedicated to preventing blindness and improving the anatomical and visual outcomes, as well as the quality of life for nAMD patients.

Meet Orsight Team

Unmet Need

Current treatments fail up to 50% of nAMD patients, resulting in significant vision loss or blindness. Additionally, up to 67% of patients still experience persistent retinal fluid after two years of treatment.

Prevalence and Incidence: Approximately 1.5-1.7 million Americans are affected,

with around 300,000 new cases annually.

Innovative Solution

Orsight Pharma is developing a First-in-class drug aimed at preserving vision and preventing blindness through a breakthrough mechanism, offering new hope for those unresponsive to existing treatments.

- Small Molecule Advantage

- Prevents Blindness Through a Unique Mechanism

- Slow Release Formulation

- Complementary to Current Treatments